Ferroptosis Inhibitor Meta-Analysis for Cisplatin-Induced Kidney Injury

Supplementary file 3 from a 2026 multilevel meta-analysis by Burcu Yuksel, synthesizing preclinical evidence on ferroptosis inhibition for renoprotection. The dataset likely contains extracted data from 58 preclinical studies, including 265 effect sizes on renal function and ferroptotic biomarkers. It was published on figshare under a CC-BY-4.0 license.

Use Cases

• Meta-regression analysis of treatment efficacy based on outcome type (e.g., BUN, SCr, GPX4) as a moderator.
• Assessing the pooled effect sizes (Hedges’ g) of natural versus synthetic ferroptosis inhibitors.
• Investigating heterogeneity and small-study effects in preclinical research on the System Xc−/GSH/GPX4 axis.

Strengths

• Data extracted from 58 unique preclinical studies following PRISMA 2020 guidelines.
• Includes 265 effect sizes across multiple biomarkers (BUN, SCr, GPX4, GSH, MDA, 4-HNE, Fe2+).
• Analysis employed a three-level random-effects model and multilevel meta-regression.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The meta-analysis indicates significant residual heterogeneity and potential inflation of pooled estimates due to small-study effects.

Provenance

Source

Burcu Yuksel via figshare.

Collection Method

Systematic review and multilevel meta-analysis of studies from PubMed and Web of Science.

Freshness

Last updated 2026-05-04 05:33:15.